Evidence map›Paper›PMID 23636094›Full record

ArticleScience translational medicine2013

Angiotensin-converting enzyme-induced activation of local angiotensin signaling is required for ascending aortic aneurysms in fibulin-4-deficient mice.

Jianbin Huang, Yoshito Yamashiro, Christina L Papke, Yuichi Ikeda, Yanling Lin, Miteshkumar Patel, Tadashi Inagami, Victoria P Le, Jessica E Wagenseil, Hiromi Yanagisawa

Abstract read
In one paragraph

Article in Science translational medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 52 citations in OpenAlex.

  1. IL-6/gp130 signaling in CD4Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  2. Review
  3. Protective Role of Endothelial Fibulin-4 in Valvulo-Arterial Integrity.Journal of the American Heart Association · 2023
    Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Therapies for Thoracic Aortic Aneurysms and Acute Aortic Dissections.Arteriosclerosis, thrombosis, and vascular biology · 2019
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Jianbin HuangDepartment of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390-9148.
Yoshito Yamashiro *Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390-9148.
Christina L Papke *Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390-9148.
Yuichi Ikeda *Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, TX 75390-9148.
Yanling LinDepartment of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390-9148.
Miteshkumar PatelDepartment of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390-9148.
Tadashi InagamiDepartment of Biochemistry, School of Medicine, Vanderbilt University, Nashville, TN 37235.
Victoria P LeDepartment of Biomedical Engineering, St. Louis University, St. Louis, MO 63103-2010.
Jessica E WagenseilDepartment of Biomedical Engineering, St. Louis University, St. Louis, MO 63103-2010.
Hiromi YanagisawaDepartment of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390-9148.
The University of Texas Southwestern Medical Center · USUniversity of Missouri–St. Louis · USHoward Hughes Medical Institute · USVanderbilt University · US

Funding

TRAINING IN CARDIOVASCULAR RESEARCHT32HL007360 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI HILL, JOSEPH A · 1985 to 2012
$11.8M
Angiotensin Receptor AT1 in Vascular Cell Control.R37HL058205 · NHLBI · VANDERBILT UNIVERSITY · PI INAGAMI, TADASHI · 2001 to 2010
$3.6M
VESSEL STIFFENING, HYPERTENSION, AND VASCULAR EXTRACELLULAR MATRIXR01HL105314 · NHLBI · WASHINGTON UNIVERSITY · PI MECHAM, ROBERT P., WAGENSEIL, JESSICA · 2010 to 2018
$3.2M
Loss of Matrix Regulation and Aortic Aneurysm Development in vivoR01HL106305 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI YANAGISAWA, HIROMI · 2011 to 2014
$1.5M
BIOMECHANICAL FACTORS IN CONGENITAL VASCULAR DISEASER01HL115560 · NHLBI · WASHINGTON UNIVERSITY · PI WAGENSEIL, JESSICA · 2012 to 2015
$1.5M
The Role of Fibulin-5 in Cardiovascular RemodelingR01HL071157 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI YANAGISAWA, HIROMI · 2003 to 2007
$1.4M
Mechanical Signals in Vessel DevelopmentR00HL087563 · NHLBI · SAINT LOUIS UNIVERSITY · PI WAGENSEIL, JESSICA · 2009 to 2011
$747k
NHLBI NIH HHS 5T32HL007360-34NHLBI NIH HHS R00 HL087563NHLBI NIH HHS R00HL087653NHLBI NIH HHS R01 HL071157NHLBI NIH HHS R01 HL105314NHLBI NIH HHS R01HL105314NHLBI NIH HHS R01 HL106305NHLBI NIH HHS R01HL106305NHLBI NIH HHS R01 HL115560NHLBI NIH HHS R37 HL058205NHLBI NIH HHS R37HL58205NHLBI NIH HHS T32 HL007360
6 · The paper itself

Abstract

Aortic aneurysms are life-threatening and often associated with defects in connective tissues and mutations in smooth muscle cell (SMC) contractile proteins. Despite recent advances in understanding altered signaling in aneurysms of Marfan syndrome, the underlying mechanisms and options for pharmacological treatment for other forms of aneurysms are still under investigation. We previously showed in mice that deficiency in the fibulin-4 gene in vascular SMCs (Fbln4(SMKO)) leads to loss of the SMC contractile phenotype, hyperproliferation, and ascending aortic aneurysms. We report that abnormal up-regulation of angiotensin-converting enzyme (ACE) in SMCs and subsequent activation of angiotensin II (AngII) signaling are involved in the onset of aortic aneurysms in Fbln4(SMKO) mice. In this model, aneurysm formation was completely prevented by inhibition of the AngII pathway with losartan or captopril within a narrow therapeutic window during the first month of life, even though the altered mechanical properties of blood vessel walls were not reversed by the pharmacological treatment. The therapeutic effects of losartan in Fbln4(SMKO) mice do not require the AngII receptor type 2 (Agtr2) but likely require both type 1a (Agtr1a) and 1b (Agtr1b) receptors. The results indicate that fibulin-4 is a vascular matrix component required for regulation of local angiotensin signaling and development and maintenance of the SMC phenotype.

Indexed as

Signal TransductionAngiotensin IIAnimalsAortaAortic AneurysmBiomarkersBiomechanical PhenomenaBlood PressureCaptoprilCell DifferentiationExtracellular Matrix ProteinsExtracellular Signal-Regulated MAP KinasesGene DeletionLosartanMaleMiceAngiotensin IIBiomarkersCaptoprilEFEMP2 protein, humanExtracellular Matrix ProteinsExtracellular Signal-Regulated MAP KinasesLosartanPeptidyl-Dipeptidase AReceptor, Angiotensin, Type 1Receptor, Angiotensin, Type 2

Identifiers

PMID23636094
PMCPMC3867808
OpenAlexW2112718601

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.